BioXcel Therapeutics Inc
NASDAQ:BTAI
Relative Value
The Relative Value of one BTAI stock under the Base Case scenario is 7.45 USD. Compared to the current market price of 2.63 USD, BioXcel Therapeutics Inc is Undervalued by 65%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
BTAI Competitors Multiples
BioXcel Therapeutics Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
BioXcel Therapeutics Inc
NASDAQ:BTAI
|
78.7m USD | 57 | -0.4 | -0.7 | -0.7 | ||
US |
Abbvie Inc
NYSE:ABBV
|
281.9B USD | 5.2 | 58.5 | 12.7 | 19.4 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
144.5B USD | 5.1 | 21.5 | 16.1 | 24.1 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.4B USD | 10.4 | 28.3 | 22.6 | 23.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
96.6B USD | 7.4 | 24.4 | 16.1 | 17.7 | ||
AU |
CSL Ltd
ASX:CSL
|
132B AUD | 6.1 | 34.9 | 21.2 | 26.2 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.5B USD | 3 | 14.4 | 7.9 | 10.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
41.2B USD | 6 | -8.7 | -9.2 | -7.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
30.3B USD | 3.1 | 26.1 | 14.2 | 17.6 | ||
KR |
Celltrion Inc
KRX:068270
|
36.6T KRW | 16.8 | 68.3 | 41.9 | 57.7 |